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Abstract
DYRK1A is a pleiotropic protein kinase with diverse functions in cellular regulation, includ-
ing cell cycle control, neuronal differentiation, and synaptic transmission. Enhanced activity
and overexpression of DYRK1A have been linked to altered brain development and function
in Down syndrome and neurodegenerative diseases such as Alzheimer’s disease. The
β-carboline alkaloid harmine is a high affinity inhibitor of DYRK1A but suffers from the
drawback of inhibiting monoamine oxidase A (MAO-A) with even higher potency. Here we
characterized a series of novel harmine analogs with minimal or absent MAO-A inhibitory
activity. We identified several inhibitors with submicromolar potencies for DYRK1A and
selectivity for DYRK1A and DYRK1B over the related kinases DYRK2 and HIPK2. An opti-
mized inhibitor, AnnH75, inhibited CLK1, CLK4, and haspin/GSG2 as the only off-targets in
a panel of 300 protein kinases. In cellular assays, AnnH75 dose-dependently reduced the
phosphorylation of three known DYRK1A substrates (SF3B1, SEPT4, and tau) without neg-
ative effects on cell viability. AnnH75 inhibited the cotranslational tyrosine autophosphoryla-
tion of DYRK1A and threonine phosphorylation of an exogenous substrate protein with
similar potency. In conclusion, we have characterized an optimized β-carboline inhibitor as
a highly selective chemical probe that complies with desirable properties of drug-like mole-
cules and is suitable to interrogate the function of DYRK1A in biological studies.
Introduction
Protein kinases are pharmacologically tractable proteins that have key roles in most, if not all,
cellular signalling pathways. Although protein kinases have become one of the most intensively
pursued classes of drug targets, selective inhibitors suitable for functional experiments exist
only for a fraction of the human kinome [1,2]. Although RNA interference and genetic knock-
out techniques provide valuable functional information, small molecules can inhibit kinase cat-
alytic activity without perturbing the function of other domains that have independent
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functions in many protein kinases [3]. Thus, high quality chemical probes are needed for the
functional characterisation of the>500 human protein kinases and their evaluation as poten-
tial drug targets [4–6].
Protein kinases of the DYRK family are dual specificity kinases that phosphorylate sub-
strates only on serine or threonine residues but autophosphorylate on tyrosine, which is an
essential step for full activation of the enzymes [7–9]. DYRK1A has attracted increasing inter-
est as a potential drug target due to its role in the pathology of Down syndrome and the pro-
posed involvement in neurodegenerative diseases and cancer (for reviews, see [10–14]). Owing
to the localisation of the human DYRK1A gene on chromosome 21, the over-activity of
DYRK1A that results from the increased dosage of the DYRK1A gene is thought to contribute
to the neurological abnormalities associated with Down syndrome [15]. The function of
DYRK1A in neurogenesis and neuronal differentiation is well supported by evidence from cell
culture, transgenic mouse models and human disease [11,16–17]. At least in mice, DYRK1A
overexpression results also in postnatal electrophysiological and cognitive alterations, suggest-
ing that this phenotype might be amenable to pharmacological intervention [18]. Indeed, the
effects of DYRK1A overexpression on brain function in transgenic mice can be partially res-
cued in adult animals by downregulation or inhibition of DYRK1A [19–21].
DYRK1A is a pleiotropic kinase that is ubiquitously expressed and phosphorylates many
proteins unrelated to neuronal differentiation and function [11,22–24]. The participation of
DYRK1A in the regulation of many cellular processes, such cell survival, quiescence, mRNA
splicing, endocytosis and transcriptional regulation is often supported by the effects of kinase
inhibitors. DYRK1B is a paralogous kinase closely related with DYRK1A (85% identical amino
acids in the catalytic domain) and is overexpressed in certain cancer types, where it favours the
arrest of cells in a quiescent state to allow cellular repair [25–26]. Interestingly, a gain-of-func-
tion point mutation in DYRK1B has been identified as causative for a familial form of the meta-
bolic syndrome [27]. A highly selective small-molecule inhibitor of DYRK1A and DYRK1B
will be instrumental in defining the physiological substrates and downstream effects that are
regulated by these kinases.
The plant alkaloid harmine is one of the most potent and selective DYRK1A inhibitors
presently available [13–14,28]. Enzymatic studies and the analysis of the DYRK1A/harmine
cocrystal have characterized harmine as an ATP competitive inhibitor that binds to the active
conformation of the kinase domain (type I inhibitor) [29–30]. Nevertheless, harmine proved to
be highly selective for DYRK1A and DYRK1B in a kinome screen [31]. Importantly, harmine
inhibits DYRK1A-dependent phosphorylation events in cultivated cells with similar potency as
the recombinant kinase, which indicates that harmine is cell-permeable and can inhibit
DYRK1A at normal cellular ATP concentrations [28]. Therefore, harmine is frequently used to
scrutinize the presumed role of DYRK1A in cellular processes [14]. However, the use of har-
mine as a chemical probe for DYRK1A and DYRK1B is compromised by the fact that it is also
a high affinity inhibitor of monoamine oxidase A (MAO-A). Actually, harmine is commonly
used as a tracer in positron emission tomography (PET) studies for the specific visualization
and quantification of MAO-A in human brain [32].
Based on the already favorable properties of harmine as a kinase inhibitor, we have synthe-
sized a series of substituted harmine analogs with reduced MAO-A inhibitory action. The pres-
ent study aims to select from this panel the best chemical probe for DYRK1A. We have
extensively studied the most promising new β-carbolines for their kinase selectivity and their
efficacy in cell based assays. These studies identified compounds with minimal (AnnH31) or
absent (AnnH75) effect on MAO-A activity and very high kinase selectivity that are potently
suppress the phosphorylation of DYRK1A substrates in cultured cells.
Novel β-Carboline DYRK1A Inhibitors
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Results and Discussion
Kinase selectivity of the novel β-carboline DYRK1A inhibitors
An extensive panel of new harmine analogs was designed and synthesized in order to develop a
new DYRK1A inhibitor without MAO-A inhibitory activity (unpublished work). From this
series, we selected those compounds for the present analysis that showed comparable or better
inhibition of DYRK1A than harmine (> 60% inhibition at a concentration of 1 μM) and did
not inhibit MAO-A (<5% at 1 μM). As an exception, AnnH31 was included although it weakly
inhibited MAO-A in the primary screen (25% inhibition at 1 μM).
First, the new β-carbolines were examined for selectivity against kinases that are typical tar-
gets of other DYRK1A inhibitors, i.e. DYRK1B, DYRK2, HIPK2 and CLK1. Overall, most com-
pounds showed a similar selectivity profile towards these kinases (Fig 1). The more potent
DYRK1A inhibitors also inhibited DYRK1B, although slightly less efficiently than DYRK1A.
In contrast to 5-iodotubercidin, which we used as a reference compound, the β-carbolines
inhibited DYRK2 and HIPK2 only weakly. Similar to other DYRK1A inhibitors, most com-
pounds were also active against CLK1 [14,31].
To further characterize the selectivity of three promising compounds, we determined IC50
values for the inhibition of MAO-A and DYRK1A. In this experiment we measured DYRK1A
activity by a radioactive assay, which is considered the gold standard for measuring kinase
activities [33]. This assay identified AnnH31 as the most potent DYRK1A inhibitor with an
IC50 of 81 nM, followed by AnnH75 and AnnH43 (Table 1). N9-substituted harmine deriva-
tives (AnnH31 and AnnH43) were less active towards MAO-A. The N9-cyanomethyl
Fig 1. Inhibition of DYRK1A and related kinases by selected β-carbolines. Kinase activities are given as the means of at least 3 measurements in the
presence of 1 μM of the compounds (10 μM in HIPK2 assays) and are expressed as the percentage of the uninhibited control (Kinase-GLO assay).
5-iodotubercidin (IoT) served as a structurally unrelated control compound that inhibits all tested kinases.
doi:10.1371/journal.pone.0132453.g001
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derivative of harmine, AnnH31, inhibited MAO-A with an IC50 of 3.2 μM, which translates to
40 fold selectivity for DYRK1A over this off-target. The concept of using N-alkylation of har-
mine to reduce MAO-A inhibition has previously been exploited by Drung et al. [34], who
showed that N9-heptyl harmine inhibits MAO-A much less potently than DYRK1A (13% vs.
85% inhibition at a concentration of 1 μM). Eventually, we achieved the complete elimination
of MAO-A inhibition by generating the 1-chloro analog of AnnH31, AnnH75. Considering
our aim to achieve maximal selectivity for DYRK1A over MAO-A, we opted for AnnH75 as
the most useful compound. Regarding the intended use in animal experiments, we also specu-
lated that the chlorination of ring A might increase metabolic stability of AnnH75.
Docking analysis
To rationalize the observed in vitro inhibition data and to analyse the interaction with the
selected kinases we performed a molecular docking study. As observed in the X-ray structure
of DYRK1A complexed with harmine, the analog AnnH75 could be docked in a similar way to
DYRK2, HIPK2 and CLK1 (Fig 2). AnnH75 interact with the residues of the ATP binding
pocket and is involved in two hydrogen bonds–one to the hinge region (backbone NH of L241)
and one to the conserved K188 (Fig 2A). The cyanomethyl substituent R4 is buried under the
P-loop of DYRK1A and makes favourable van-der-Waals interaction with G166 (distance
shown in Fig 2). The same binding mode was observed for DYRK1B where only one residue of
the binding pocket differs from DYRK1A (L192 instead of M240 in DYRK1A) (Fig. B in S1
File). The inhibitor binding site of DYRK2 is also similar to that of DYRK1A with just three
residues that are different (Fig 2B). V222 in DYRK1A is changed to an isoleucine in DYRK2
(I212), while the DYRK1A hinge residue M240 is changed to a leucine in DYRK2 (L230),
which slightly decreases the hydrophobicity of the pocket. The residue that precedes the DFG
motif (V306 in DYRK1A and I294 in DYRK2) appears to be more important. I212 and I294 in
DYRK2 are more bulky than the corresponding residues in DYRK1A and change the size of
the entrance of the ATP pocket, which seems to be less favourable for the N9-substituted har-
mine analogs studied in the current work. However, this point cannot be demonstrated with
the simple docking models presented here.
The HIPK2 ATP binding pocket shows the largest structural deviation compared to
DYRK1A (Fig 2C and 2E). As a consequence, the van-der-Waals interaction between M331 in
HIPK2 and the carboline ring of AnnH75 is less favourable compared to L294 in DYRK1A.
Interestingly, the binding pocket of CLK1 is more similar to DYRK1A, although CLK1 is a
more distant member of the family. Two residues in contact with the inhibitor are different:
M240 in DYRK1A is changed to L243 in CLK1 (L241 in CLK4) and I165 in DYRK1A is
Table 1. Inhibition of DYRK1A and MAO-A by selected β-carbolines.
Compound Inhibition of DYRK1Aa Inhibition of MAO-Aa





a Calculated by curve fitting from n = 3–5 independent concentration response curves shown in Fig. A in S1
File.
b Range of published values [28,29,56].
doi:10.1371/journal.pone.0132453.t001
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changed to L167 (L165 in CLK4), respectively (Fig 2D and 2E). The third difference (S242 in
DYRK1A changed to G245 in CLK1) is not in direct contact with the inhibitor. Due to the
high similarity of the ATP binding pocket (shape and hydrophobicity), the docking pose of
AnnH75 for CLK1 (and CLK4) is nearly identical to the one observed for DYRK1A/B and
explains the observed inhibitory activity of AnnH75 for CLK1.
Kinome profiling
The selectivity of AnnH75 was profiled against a panel of 300 kinases at a concentration of
1 μM (Table A in S1 File). These activity assays identified CLK1, CLK4, haspin (gene symbol
Fig 2. Analysis of kinase inhibitor interactions. A-D, Predicted binding modes of AnnH75 at DYRK1A and related kinases. The inhibitor is colored cyan
and kinases are depicted as ribbon structures. Only relevant amino acid residues in the ATP binding pocket are shown for clarity. In B-D, residues different
from DYRK1A are colored green and labeled. The distances of the two hydrogen bonds (red line) and the distance between the cyano group and the glycine
of the P-loop (G166 in DYRK1A) are given in Angstrom. (DYRK1A, PDB ID 3ANR; DYRK2 PDB ID 4AZF; HIPK2, homology model, CLK1, PDB ID 2VAG). E,
Comparison of amino acid residues relevant for AnnH75 binding. In the left, the relationship of the kinases is illustrated by the sequence identity of their
catalytic domains. Residues generally conserved in protein kinases (G166, K188, D307) and the gatekeeper residue (F238) are highlighted by bold print.
Residues different from DYRK1A are shown with their position in the sequence. Differences correlating with kinase resistance to AnnH75 are highlighted in
red.
doi:10.1371/journal.pone.0132453.g002
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GSG2), DYRK1A and DYRK1B as the kinases most strongly inhibited by AnnH75 (Fig 3A).
The cross-kinase activity towards CLK1/4 is typical for DYRK1A/B inhibitors with published
selectivity data, suggesting that these kinases share a similar geometry of their ATP binding
pockets (Table 2). Nevertheless, two new compounds derived from different scaffolds were
recently reported to exhibit 100-fold selectivity for DYRK1A over CLK1 [35–36]. These com-
pounds could not be included in Table 2 because kinome profiling data are not available. Maxi-
mal specificity is a desirable goal for a chemical probe, whereas polypharmacology may be
acceptable for a drug [6]. In fact, the combined DYRK1A/CLK1 inhibitory activity has been
proposed to be advantageous to correct the dysregulated alternative splicing of tau mRNA,
because both kinases are thought to favour the generation of pathogenic tau species [37]. On
the other hand, the issue of potentially redundant functions of the CLKs is not yet sufficiently
clear, so that the relative resistance of CLK2 and CLK3 to the inhibitors may allow these
kinases to compensate for the effects of CLK1/4 inhibition.
AnnH75 and harmine lack cross-reactivity for the related kinases DYRK2, DYRK3 and
HIPK1-3, which presents a clear advantage over L41, INDY and LDN-211898. Thiophene 29
does not inhibit the HIPKs, but targets DYRK2 (Table 2).
The DYRK, HIPK and CLK families are neighbours in the CMGC branch of the phyloge-
netic kinome tree (Fig 3A). The only other off-target of AnnH75 was haspin (gene name
GSG2), an atypical protein kinase with limited amino acid sequence similarity to the DYRK/
CLK families. Dual inhibition of DYRKs and haspin has previously been observed for other β-
carbolines [38] but also for structurally divergent inhibitors such as acridine compounds [39],
5-iodotubercidin [40] and the anthrapyrazolone SP600125 [41]. The best characterized func-
tion of haspin is the phosphorylation of Thr3 in histone H3 during mitosis [42]. Knockdown
of haspin in human cell lines has been reported to cause mitotic arrest [43].
Fig 3. Selectivity profile of AnnH75. AnnH75 was profiled at a concentration of 1 μM against a panel of 300
protein kinases (see Table A in S1 File for the complete results). A, Target kinases inhibited by more than
50% are indicated. The kinome dendrogramwas adapted and is reproduced courtesy of Cell Signaling
Technology. B, Calculation of the Gini coefficient as a measure of kinase selectivity. The Lorenz curve
illustrates the degree to which the total inhibitory activity of a compound (i.e. the sum of inhibition of all tested
kinases) is equally distributed among all tested kinases (bisector line, Gini coefficient of 0) or directed towards
a single kinase (maximal selectivity, a Gini coefficient of 1).
doi:10.1371/journal.pone.0132453.g003
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To compare the overall kinase inhibitor selectivity of AnnH75 and other inhibitors, we cal-
culated a selectivity score (S) for each compound by dividing the number of target kinases
(< 50% residual activity) by the total number of tested kinases. As a second measure of selectiv-
ity, we determined the Gini coefficient, which does not depend on defining an arbitrary hit
threshold (Fig 3B) [44]. According to these metrics, AnnH75 is as selective as harmine and
superior to INDY [30,45]. The higher Gini values of L41 and thiophene 29 are likely due to the
higher inhibitor concentrations used in these screens, as the Gini coefficient is highly depen-
dent on the inhibitor concentration [44]. This is exemplified by the data sets for 1 μM and
10 μM harmine in Table 2.
Cytotoxicity
To evaluate the usability of the new DYRK1A inhibitors in cell culture experiments, we ana-
lyzed the effect of AnnH75 and other harmine analogues on the viability of three different
clonal cell lines, HeLa cells and the neuronal cell lines PC12 and SH-SY5Y. Viability assays
showed that treatment with up to 10 μMAnnH75 for 3 days caused minimal cytotoxicity in
Table 2. Kinome selectivity of AnnH75 and published DYRK1A inhibitors.a


















CLK1 0 - 0 0 2 1 0 4
CLK2 43 10 3 6 10 12 1 28
CLK3 74 - 42 2 73 30 63 88
CLK4 0 - 2 0 2 0 - 0
DYRK1A 8 2 0 0 2 0.23 μMb 0 10
DYRK1B 8 - 2 4 11 0.24 μMb 2 0
DYRK2 68 35 61 1 57 3 14 7
DYRK3 57 31 - - - 0 3 34
DYRK4 94 - - - - 13 - 87
HIPK1 91 119 14 1 34 64 59 96
HIPK2 87 68 34 11 60 - 47 -
HIPK3 88 118 44 4 45 - 51 -
HIPK4 88 - 90 44 91 - 72 93
IRAK1 95 - 66 3 100 - 47 -
PIM1 41 74 85 15 73 2 9 78
PIM2 107 101 43 41 82 - 36 93
PIM3 44 74 78 27 71 - 11 -
Haspin 5 0.59 μMc - - - - 0 -
Number of
kinases
300 117 402 402 402 66 292 102
Reference [45] [31] [31] [31] [30] [38] [57]
Gini score 0.625 0.628 0.843 0.673 0.862 0.342 0.652 0.741
Selectivity
score
0.04 0.04 0.06 0.09 0.02 0.26 0.16 0.1
a Structures are shown in Fig. D in S1 File.
b IC50 values are given because %-activity values are not given in the reference.
c IC50 value taken from Cuny et al. [38]
doi:10.1371/journal.pone.0132453.t002
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HeLa and PC12 cells (Table 3), whereas AnnH24, AnnH31 and AnnH43 reduced cell viability
when used at high concentrations. We have previously found cytotoxic effects of harmine at
concentrations of>3 μM in HeLa and HEK293 cells [28]. The SH-SY5Y neuroblastoma cell
line was more sensitive towards all tested compounds than the other two cell lines. Of note,
AnnH75 was used at concentrations sufficient for maximal inhibition of haspin without
markedly affecting the viability of HeLa and PC12 cells. In contrast, the haspin inhibitor CHR-
6494 caused dose-dependent reduction of viability of three different cell lines by blocking cell
cycle progression and inducing mitotic spindle abnormalities with large defects in chromo-
somal alignment [46]. The lack of toxicity of AnnH75 in the viability assay suggests haspin
inhibition does not inevitably result in mitotic arrest, since the XTT assay is sensitive the cell
number and thus to changes in the proliferation rate.
Inhibition of DYRK1A activity in cell culture
To evaluate the new harmine analogues for their capacity of inhibiting DYRK1A in cell
culture experiments, we compared the effect of AnnH75 and other select compounds on the
DYRK1A-catalysed phosphorylation of splicing factor 3b1 (SF3B1). Phosphorylation of SF3B1
on Thr434 closely reflects the cellular activity of endogenous DYRK1A and provides a useful
measure for the cellular efficacy of DYRK1A inhibitors [28]. HeLa cells were transiently trans-
fected with a GFP-SF3B1 expression vector and treated with three of the new β-carbolines
(AnnH31, AnnH43, AnnH75) in parallel with three established DYRK1A inhibitors (harmine,
L41, INDY). Western blot analysis showed that the new inhibitors reduced the phosphoryla-
tion of SF3B1 with potencies similar to harmine and L41 and were more active than the ben-
zothiazole INDY (Fig 4).
We next analysed the phosphorylation of SEPT4 by DYRK1A, which can be detected by
means of its reduced electrophoretic mobility [47]. Treatment of HeLa cells expressing FLAG-
SEPT4 with AnnH31 and AnnH75 resulted in a concentration-dependent decrease of intensity
of the slower migrating band and a concomitantly increased signal of the lower band (Fig 5A).
Consistent with the IC50 values determined in the in vitro-assays (Table 1), AnnH31 reduced
SEPT4 phosphorylation more potently than AnnH75.
As a third cell-based assay of DYRK1A inhibition, we measured the phosphorylation of the
microtubule-associated protein tau by DYRK1A. The phosphorylation of tau (gene symbol
MAPT) by DYRK1A has been considered potentially relevant in the early Alzheimer’s disease-
Table 3. Cytotoxicity of selected compounds.a
HeLa PC12 SY5Y
1 μM 3 μM 10 μM 1 μM 3 μM 10 μM 1 μM 3 μM 10 μM
AnnH24 97 96 72 95 90 81 75 66 45
AnnH31 93 80 55 89 88 70 81 88 38
AnnH43 91 80 66 88 88 90 61 68 45
AnnH75 100 93 92 94 100 95 89 73 43
IoTb 67 16 18 62 17 5 13 10 15
Staurosporinec 8 18 6
a Viability of treated cells (HeLa, PC12 and SH-SY5Y) is given in percent relative to untreated control cells (means of two experiments with triplicate
measurement).
b 5-Iodotubercidine (IoT) is a DYRK/CLK inhibitor that inhibits viability by acting on an off-target (adenylate kinase).
c Staurosporine is known to induce apoptosis and served as a positive control.
doi:10.1371/journal.pone.0132453.t003
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like neurodegeneration in Down syndrome and in spontaneous Alzheimer’s disease [10]. In
this assay, AnnH75 inhibited DYRK1A activity with an IC50 of 1 μM (Fig 5B and 5C). The
higher value as compared to the inhibition of SEPT4 phosphorylation (0.36 μM) may be due to
the overexpression of DYRK1A in this assay. AnnH31, L41 and 5-iodotubercidin were the
best inhibitors in this assay, whereas INDY reduced tau phosphorylation less efficiently. Low
cellular potency of INDY has previously been observed in assays of tau phosphorylation and
reporter gene activity [30]. Similarly, two other DYRK1A inhibitors with excellent potency and
selectivity in biochemical assays require ~1000 higher concentrations to inhibit tau phosphory-
lation in cellular assays [35–36]. Taken together, our results provide evidence that AnnH31
and AnnH75 can be used as chemical probes to confirm the participation of DYRK1A in cellu-
lar phosphorylation events.
Fig 4. Inhibition of SF3B1 phosphorylation by DYRK1A in HeLa cells.HeLa cells expressing
GFP-SF3B1-NT were treated with the indicated compounds for 18 h. The phosphorylation state of SF3B1
was determined by immunoblotting with pT434 antibody, and the results were normalized to the total amount
of SF3B1 immunoreactivity. A, Representative western blots. AnnH79 is a harmine analogue that does not
inhibit DYRK1A and was used as negative control. The vertical line indicates where irrelevant lanes were
deleted from the final image. B, The column diagram summarizes the quantitative evaluation of 3–6
experiments for each compound (means + SD).
doi:10.1371/journal.pone.0132453.g004
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AnnH75 inhibits tyrosine autophosphorylation of DYRK1A
Tyrosine kinase activity of DYRKs has been postulated to exhibit different inhibitor sensitivity
than serine/threonine phosphorylation [7]. Therefore we investigated if AnnH75 is a selective
inhibitor of the serine/threonine kinase activity of mature DYRK1A or whether AnnH75 also
interferes with tyrosine autophosphorylation during translation. To address this question, we
used a coupled in vitro-transcription-translation system and monitored at the same time the
effect of the inhibitor on the tyrosine autophosphorylation of DYRK1A and the phosphoryla-
tion of Thr434 in the substrate protein SF3B1 (Fig 6). Under these conditions, AnnH75 inhib-
ited tyrosine autophosphorylation of DYRK1A at concentrations>1 μM. Slightly higher
concentrations of AnnH75 were required for the inhibition of threonine phosphorylation in
SF3B1. The higher IC50 value for SF3B1 phosphorylation as compared to the peptide assay is
due to the fact that kinase activity in the in vitro-translation mix cannot be assayed under con-
ditions of substrate saturation (as discussed previously [9]). In conclusion, AnnH75 inhibits
both the immature and mature form of DYRK1A.
Conclusions
Chemical probes serve as invaluable small molecule tools to functionally annotate signalling
proteins, to understand their role in physiological and pathological processes and to validate
them as potential drug targets. Here we report the evaluation of new harmine analogs with
regard to their suitability as chemical probes for the protein kinase DYRK1A. To support the
conclusion that AnnH31 and AnnH75 meet the key requirements of a useful tool for this pur-
pose, we discuss our results with respect of the “fitness factors” of chemical probes that were
proposed by Workman & Collins [6]: selectivity, potency, chemistry and context.
Fig 5. Inhibition of SEPT4 and tau phosphorylation by DYRK1A. A, HeLa cells transiently expressing FLAG-SEPT4 were treated with AnnH31 or
AnnH75 for 5 h before cells were lysed and analysed by immunoblotting with a FLAG-tag antibody. 5-iodotubercidin (IoT) served as positive control. Relative
SEPT4 phosphorylation was calculated as the ratio of the intensities of the phosphorylated upper band and the lower band.B, HEK293 cells with constitutive
expression of GFP-tau and regulatable expression of GFP-DYRK1A were treated with doxycyclin and the indicated inhibitors for 18 h. Phosphorylation of tau
on Thr212 was detected with a phosphospecific antibody. Expression levels of GFP-tau and GFP-DYRK1A were assessed with a GFP antibody. For
quantitative evaluation of DYRK1A inhibition, the basal pT212 signal in control cells not treated with doxycyclin (Ctrl) was subtracted from all values.C,
Quantitative evaluation of three experiments each for SEPT4 and tau. All data were standardized to the level of phosphorylation in cells untreated with
inhibitors. Error bars indicate SEM.
doi:10.1371/journal.pone.0132453.g005
Novel β-Carboline DYRK1A Inhibitors
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Selectivity
A key criterion for the use of a kinase inhibitor as a chemical probe is that its selectivity profile
is well defined [4,6]. The kinase selectivity profile of AnnH75 compares favourably with that of
other DYRK1A inhibitors that have been profiled against an informative panel of kinases
(Table 2). However, the cross-reactivity for CLK1/4 and haspin clearly requires consideration
when this DYRK1A inhibitors is used in experiments addressing splicing regulation or cell
cycle control.
Regarding off-targets outside the protein kinase family, we reached the goal of eliminating
the MAO-A inhibitory activity of harmine. AnnH31 displays already 40 fold selectivity for
DYRK1A over MAO-A and complies with the requirements for a high quality chemical probe
[6]. AnnH75 has no residual effect on MAO-A and is better suited in all applications poten-
tially susceptible to monoamine effects.
The availability of inactive analogs and active probes from a different chemical class can
help to prove target-dependency in a biological experiment [4,6]. When AnnH75 is used as a
probe to confirm a hypothetical function of DYRK1A or DYRK1B, AnnH79 can serve as a
structurally related inactive control compound (Fig 4) and L41 as a potent inhibitor with a dif-
ferent chemotype.
Fig 6. AnnH75 inhibits both threonine and tyrosine kinase activity of DYRK1A. A DYRK1A construct
with an N-terminal StrepTag 2 (ST2-DYRK1Acat) was expressed in a cell-free E. coli-derived expression
system. Coupled in vitro transcription and translation reactions were incubated for 1 h in the presence of
recombinant SF3B1-NT-His6 and AnnH75. Phosphorylation of tyrosines in DYRK1A and of Thr434 in SF3B1
was determined by immunoblotting with a phosphotyrosine-specific antibody (pTyr) and a pThr434-specific
antibody. A, Representative western blots. The asterisks mark unidentified bands.B, Quantitative evaluation.
Results were normalized to the total amount of DYRK1A or SF3B1, respectively, and are plotted relative to
the phosphorylation in the untreated control samples (means +/- SEM, n = 3).
doi:10.1371/journal.pone.0132453.g006
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Biochemical and cellular potency
Several mechanisms can account for discrepancies between inhibitor potency in biochemical
and in the cellular context [3,48]. Many DYRK1A inhibitors with adequate potencies in bio-
chemical assays (< 100 nM, as proposed by Workman & Collins [6]) have been described [14],
but only few have been shown to inhibit the phosphorylation of a cellular target in a concentra-
tion-dependent manner with a practicable potency (< 1–10 μM according to Workman & Col-
lins [6]). In particular, the only known inhibitors with significant selectivity for DYRK1A over
CLK1 require micromolar concentrations for half-maximal effects in cellular assays, in spite of
low nanonmolar potencies in biochemical assays [35–36]. We verified the cellular efficacy of
AnnH75 with three different substrates of DYRK1A and provide direct comparisons with
established DYRK1A inhibitors. Taken together, the concentration-dependent effects of the
chemical probes (AnnH31 or AnnH75) support the hypothesis that a molecular mechanism
depends on a certain target (in this case DYRK1A).
Chemistry (structure, solubility, stability, permeability)
The procedures for the synthesis and the structural characterization of the new β-carboline
compounds will be fully described in a separate manuscript, and the structure of the AnnH75/
DYRK1A cocrystal has been solved (PDB ID 4YU2). The physicochemical properties of
AnnH31 and AnnH75 comply with Lipinski’s “rules of 5”, which predict oral bioavailability of
drugs [49]) (Table B in S1 File). The efficacy in cell-based assays indicates that AnnH31 and
AnnH75 are membrane-permeable and sufficiently soluble in aqueous media. Moreover, we
found that the new substances were still active after prolonged incubation at 37°C in cell cul-
ture medium (Fig. A in S1 File). It remains to be examined whether AnnH31 and AnnH75 are
metabolically stable in animal experiments.
Context
It is to be emphasized that the appropriateness of a chemical probe depends on the hypothesis
under investigation and our knowledge of the biological context [6]. Thus, the characterization
of the effects of AnnH31 and AnnH75 on on-target and off-target pathways will help to estab-
lish the suitability of the probes in a specific context. The interpretation of the phenotypic
effects of a DYRK1 inhibitor is strengthened if the inhibition of kinase activity or the effect on
a downstream pathway can be monitored. For example, the indole derivative ID-8 was found
to maintain human stem cells in an undifferentiated state in chemically defined xeno-free
medium and was proposed to act as a DYRK inhibitor [50]. This is a very important observa-
tion, although ID-8 has not yet been scrutinized according to the fitness criteria of a chemical
probe. The presumed role of DYRK1A in this context could be further corroborated by using
AnnH75 and L41 as potent, specific and well characterized DYRK1 inhibitors in parallel with
inactive chemical analogs, and by assessing cellular DYRK1A inhibition by ID-8.
Materials and Methods
Antibodies
Mouse monoclonal antibodies against phosphotyrosine (PY99; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), SF3B1 (SAP155; MBL, Nagoya, Aichi, Japan), and FLAG-tag (FLAG
BioM2, Sigma Aldrich GmbH, München, Germany), goat antibody against GFP (Rockland
Immunochemicals Inc., Gilbertsville, PA, USA), a rabbit antibody for phosphorylated Thr212
in the tau protein (#44740G, Invitrogen, Camarillo, USA) as well as Strep-Tactin HRP
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conjugate (IBA, Göttingen, Germany) were purchased commercially. The rabbit antibody for
detecting phosphorylated Thr434 in SF3B1 has been described [51].
Chemicals
Harmine was obtained from Fluka, Buchs, Switzerland and 5-iodotubercidin from Tocris Bio-
science, Minneapolis, MN, USA. A report on the synthesis of the harmine analogues will be
presented elsewhere. All inhibitors were dissolved in dimethylsulfoxide (DMSO), except for
harmine which was dissolved in ethanol. Further dilutions of all inhibitors were prepared in
water to get final concentrations of 3% DMSO in in vitro translation reactions and cell assays
or 1% DMSO in kinase activity assays if not indicated otherwise.
Preparation of recombinant kinases
Bacterial expression plasmids for GST-DYRK1A-ΔC and GST-DYRK2 have been described
earlier [52–53]. To generate the GST-DYRK1Bcat, GST-HIPK2cat and GST-CLK1cat expres-
sion vectors, human cDNAs encoding the catalytic domain of DYRK1B (amino acids 87–451
of the reference sequence NP_004705), HIPK2 (amino acids 180–533 of the reference sequence
NP_00110671) or CLK1 (amino acids 141–484 of the reference sequence NP_004062) were
inserted into pGEX-2TK vector via engineered BamHI and EcoRI sites. Expression in logarith-
mically growing E. coli culture was performed for 3 h at 37°C (GST-DYRK1A-ΔC and
GST-DYRK2), 3 h at 26°C (GST-HIPK2cat), over night at 28°C (GST-CLK1cat) or over night
at room temperature (GST-DYRK1Bcat). GST fusion proteins were partially purified by affin-
ity adsorption to glutathione-Sepharose and stored in the elution buffer (50 mM Tris-HCl pH
8.0, 10 mM reduced glutathione) at -80°C until use.
MAO-A assay
Inhibition of monoamine oxidase A (MAO-A) was determined with the MAO-GLO Assay kit
from Promega according to the manufacturer’s instructions using 12 μU human recombinant
MAO-A and 25 μMMAO-A substrate in a total volume of 20 μL.
Kinase assays
Compounds were screened for inhibitory effects against GST-DYRK1A-ΔC, GST-DYRK1
Bcat, GST-DYRK2, GST-CLK1cat or GST-HIPK2cat using the Kinase-GLO Luminescent
Kinase Assay from Promega. Assays were performed in a total volume of 10 μL in kinase-buffer
(25 mMHepes pH 7.4, 0.5 mM DTT, 5 mMMgCl2, 5 μMATP) with appropriate peptide sub-
strates (20 μMDYRKtide for the DYRKs and 100 μMDYRKtide for HIPK2,
RRRFRPASPLRGPPK; or 100 μMRS domain-derived peptide for CLK1, GRSRSRSRSR).
Assays were started with this amount of a kinase preparation that consumed approximately
90% of the ATP in the assay (linear range of the kinase titration curve). The reactions were run
at room temperature for 30 min before 10 μL Kinase-GLO reagent was added. After incubation
at room temperature for additional 10 min, luminescence was recorded for 1 s.
Radioactive kinase assays were used to determine IC50 values of selected DYRK1A inhibi-
tors. GST-DYRK1A-ΔC was incubated with 100 μMDYRKtide, 100 μMATP, 5 μCi [γ-33P]-
ATP and variable concentrations of the inhibitors for 5 min at 30°C. Each sample was assayed
in triplicate. Reactions were stopped by pipetting aliquots of the reaction mix onto P81 phos-
phocellulose paper and immediate immersion in 5% phosphoric acid. Phosphocellulose papers
were washed at least 5 times and radioactivity was measured by scintillation counting.
Background values from samples incubated without kinase were subtracted and phosphate
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incorporation was normalized to the control samples incubated without inhibitor. IC50 values
were calculated with the help of the GRAPHPAD PRISM 5.0 program (GraphPad Software, La
Jolla, CA, USA) after automatic outlier elimination.
The profiling of AnnH75 against a 300-kinase panel was performed by ProQinase (Freiburg,
Germany) using radiometric protein kinase assays in a duplicate measurement. Gini coeffi-
cients were calculated and the Lorenz curve (Fig 3B) was plotted by applying the Microsoft
Excel spreadsheet provided by Graczyk [44].
Cell viability assay
Cytotoxicity was evaluated in HeLa, PC12 [54], originally purchased from Clontech Laborato-
ries Inc., Cat. No. 630912) and SH-SY5Y cells [17] after 3 days of incubation with the test com-
pounds by using a tetrazolium dye assay (XTT assay, AppliChem GmbH, Darmstadt,
Germany).
In vitro translation assay
The PURExpress In Vitro Protein Synthesis Kit (New England Biolabs, Beverley, MA, USA),
which is a reconstituted E. coli-based in vitro transcription-translation system, was used to
express a DYRK1A construct comprising the catalytic domain of DYRK1A fused to an N-ter-
minal Strep-tag II sequence. Reactions were run in a total volume of 10 μL with 10 ng/μL
pET-ST2-DYRK1A [9] and 80 ng/μL SF3B1-NT-His6 as a substrate [51] at 37°C for 1 h.
AnnH75 or solvent control (3% DMSO) was added as indicated. Reactions were stopped by
adding 2x Laemmli sample buffer and 5 mM EDTA. Tyrosine autophosphorylation of
DYRK1A and phosphorylation of SF3B1 on Thr434 was analysed by western blotting. Band
intensities were quantified using the AIDA Image Analyzer 5.0 program (Raytest, Strauben-
hardt, Germany).
Cellullar assays
HeLa cells were seeded in 6-well plates and transfected (400 ng/well) with expression vectors
for GFP-SF3B1NT (containing amino acids 1–492 of human SF3B1 [51]) or FLAG-Septin4
[47] (500 ng/well) using FuGENE HD (Promega, Mannheim, Germany). After 24 h, SF3B1
expressing cells were treated with inhibitors for 18 h. SEPT4 expressing cells were cultivated
for 48 h before they were incubated with the inhibitors for 5 h. Tau phosphorylation was
assayed using a HEK293 subclone with regulatable expression of GFP-DYRK1A and constitu-
tive expression of GFP-tau (HEK293-tau-Dyrk1A) that was kindly provided by Dr. Matthias
Engel (Department of Pharmaceutical and Medicinal Chemistry, Saarland University, Saar-
brücken, Germany) [55]. Expression of GFP-DYRK1A was induced with 2 μg/mL doxycyclin
before cells were treated with the inhibitors for 20 h.
In all assays, cells were lysed with 100 μL SDS lysis buffer (20 mM Tris HCl pH 7.4, 1%
SDS), samples were sonicated and cleared by centrifugation before SDS-PAGE and immuno-
blotting. Immunoreactivities were detected by enhanced chemiluminescence using HRP-cou-
pled secondary antibodies and quantified using the AIDA Image Analyzer 5.0 program
(Raytest, Straubenhardt, Germany). Relative phosphorylation of SF3B1 and tau was calculated
by normalisation to total protein levels. To calculate relative DYRK1A activity in tau assays,
the basal pT212 signal in control cells not treated with doxycyclin was subtracted from all val-
ues, and the phosphorylation in DYRK1A expressing cells not treated with inhibitors was set to
100%. SEPT4 phosphorylation was determined as the ratio of intensities of the phosphorylated
upper band to the lower band. Curve fitting for IC50 determination was done with the help of
the GRAPHPAD PRISM 5.0 program (GraphPad Software, La Jolla, CA, USA).
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